A PR Agency in Boston Working Through Seven Headlines for One Readout

Updated November 2026 · Written and maintained by the Progression Agency strategy team

The topline numbers land at 6:30 a.m., and by 7:00 the first draft headline already calls the drug effective. A PR agency in Boston that works on trial readouts strikes that draft first, because 21 CFR 312.7 says no one acting for a sponsor may represent in a promotional context that an investigational drug is safe or effective for the use under study. This page writes seven headlines for one hypothetical readout, says why six are struck, and keeps the seventh, then what the work costs. Progression is based in New York, works with Boston and Cambridge teams remotely, and offers on-site sessions on request.

Six thirty on readout morning

The call comes before the sun is up. A hypothetical Phase 2 trial has read out, the treated arm did better on the primary endpoint, and the head of research is already on the line. By seven there are three people editing one document, and the top line of it says the drug works.

The card above is a hypothetical, and the draft on it is one you have seen. It states more than the data do, and the person who wrote it is happy, which is why it is dangerous. Seven headlines are about to be written, and this page keeps one.

• Write the finding before the headline.
• Treat every verb that describes the drug as a claim.
• Keep counsel in the loop from the first draft, not the last.

What a PR agency in Boston checks before a headline leaves the building

The rule is 21 CFR 312.7(a). A sponsor or investigator, or any person acting on behalf of a sponsor or investigator, shall not represent in a promotional context that an investigational new drug is safe or effective for the purposes for which it is under investigation, or otherwise promote the drug.

A PR firm writing for the sponsor is a person acting on its behalf. The same paragraph says the provision is not intended to restrict the full exchange of scientific information concerning the drug, including dissemination of scientific findings in scientific or lay media. Its intent is to restrict promotional claims of safety or effectiveness for a use under investigation and to preclude commercialization before approval.

In plain terms, a headline can report what a trial measured. It should not tell a reader that the drug is safe or effective. Where a line falls between the two is a question for regulatory counsel, and this page does not draw it for you.

Why does this come up so often in Massachusetts?

Because the pipeline is here. In its report of January 8, 2026, MassBio said Massachusetts drug candidates grew nearly 14 percent year over year against 6.8 percent nationally, and that Massachusetts holds 16.1 percent of the national pipeline. Companies based in or with a significant presence in the state received 28 FDA approvals in 2025.

Headline one: the effective headline

“Candidate 17 proves effective in Phase 2” is the draft from 7:00 a.m. It is a short sentence with one problem: it represents that an investigational drug is effective for the use under study.

The rule’s words, safe or effective, are not a list of forbidden synonyms. A reader hears the same thing from “works”, “proven” and “cures”. When a draft uses any of them for the drug, strike the line and write what the trial measured instead.

What replaces it?

A report of the finding, with the measure named: what was measured, in whom and what happened. The finding is scientific information, which the rule does not intend to restrict. Counsel decides whether the wording stays on the finding side.

• Name the endpoint, not the verdict.
• Say what the comparison was.
• Leave out adjectives about the drug.

Headline two: the safe headline

“Candidate 17 shown safe and well tolerated” goes next. The rule names safety as plainly as effectiveness, and a trial of a hundred and twenty people does not show that a drug is safe in the sense a reader will take it.

A tolerability line is different from a safety claim, and it needs careful writing. A sentence can report which adverse events occurred and how often, as the trial recorded them. It should not turn that list into a verdict. Ask counsel to read every sentence on adverse events, including the quote from the chief medical officer.

Is “well tolerated” a safe word?

Treat it as a claim until counsel says otherwise. It reads as a conclusion about the drug, and conclusions are what the rule is about. Report the events and the rates, and let readers form their own view.

Headline three: the breakthrough headline

“Breakthrough result for Candidate 17” is promotional language, and it is struck for that reason. A word like breakthrough carries a judgment about the drug’s value that the data in a release cannot support.

Regulatory designations are a separate matter and have defined meanings. If your company holds one, say exactly what it is in the words the agency uses, and ask counsel to check the sentence. Do not borrow the word as a description of a result.

• Use a designation only in its exact, official words.
• Never use breakthrough as an adjective for data.
• Have counsel clear any sentence that mentions the agency.

Headline four: the investor headline

“Candidate 17 results open a path to a billion dollar market” speaks to investors, and it is struck from a headline meant for the press. It is also the one most likely to be written by someone outside the communications team.

Statements to investors about trial results raise securities questions that this page does not answer. Those belong to securities counsel, who should read every release before it goes, including a release meant only for reporters. Separate documents for separate audiences are easier to defend than one document trying to do both.

Who should read the investor version?

Securities counsel, and the company’s investor relations lead. The communications team should not be the last reader of anything that moves a stock.

Headline five: the patient headline

“New hope for people living with the condition” is written for patients, and it is struck because a patient reading it could take an investigational drug for a treatment that exists. Readers who are ill look for good news, and they read headlines closely.

The investigational status has to sit in the words a patient reads, not in a footnote. If the release goes to patient organizations, say plainly that the drug is under study, that it has not been approved, and where a patient can learn about taking part in a trial. Counsel should read that sentence too.

• Put “investigational” in the first paragraph.
• Say the drug is not approved.
• Avoid words that promise relief.
• Point to the trial listing for anyone who wants to take part.

Headline six: the data dump

“Candidate 17 Phase 2: 31.2% vs 18.4%, p=0.03, hazard ratio 0.64, 47 adverse event categories” is struck for a different reason. It breaks no promotion rule on its face, and no reporter can use it.

A headline is the place for one finding. The tables belong in the release body, the poster or the paper. A team that crams the numbers into the headline has usually not agreed on which finding matters most, and the argument is better settled before the readout than after.

Which number belongs in the headline?

At most one, the one tied to the primary endpoint, and only if counsel is comfortable with how it is phrased. Everything else goes below it.

The six cards above are the headlines struck so far, each with its reason. Only one left.

Headline seven: the one that runs

“Phase 2 trial of investigational Candidate 17 meets primary endpoint, company reports” is the headline that runs. It reports a finding, names the drug as investigational and attributes the news to the company.

What it says: the trial reached its primary endpoint, according to the company. What it does not say: that the drug is safe, that it is effective, that it will be approved or that anyone should take it. Counsel may still change the wording, and a good release leaves room for that.

• Attribute the result to the company.
• Name the drug as investigational.
• Stop at what the trial measured.
• Keep the same words in the headline, the body and the social post.

Who writes the status line?

The communications lead writes it, and regulatory counsel approves it. Keep the same sentence in every document from the release to the investor deck, so a reader never meets two versions.

• Keep a library of approved status sentences.
• Add the date each sentence was approved.
• Reuse the sentence, rather than rewriting it under deadline.
• Flag any new sentence for counsel.

What readout PR costs

Readout work is a project on top of an ongoing relationship, and the cost depends on how many audiences the release has to serve. A single release for the press is a smaller job than a package for press, investors and patient organizations, each with its own counsel review.

Published bands for PR work

The bands run from the typical low to the published high for each kind of arrangement.

Progression’s published retainers

These are Progression’s own prices, listed apart from the market bands above.

Our public relations agency page explains what each retainer covers, and healthcare public relations describes the sector work. Counsel’s fees are separate.

• Write the finding first.
• Strike the claims.
• Add the status.
• Send to counsel before anyone else sees it.

Do I need seven headlines every time?

No. The seven here are a way to see the mistakes. In practice a team writes the finding, strikes the claims and reaches a headline like the seventh in a few drafts.

A brief for your head of communications

Copy this card into a document and fill it in before a readout. A team that arrives with it can draft the seven headlines in an hour and spend the rest of the morning on the sentence that will run.

Send the filled card with the last draft your counsel changed. Our public relations agency page describes the services that follow. If your Boston business is not in biotech, marketing agency in Boston has its own page.

Related services and guides

Pages that sit beside this readout:

• Public relations agency
• Healthcare public relations
• Marketing agency in Boston

Frequently asked questions